Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 26, 375-390, April 1, 1966]
© 1966 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bradner, W. T.
Right arrow Articles by Pindell, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bradner, W. T.
Right arrow Articles by Pindell, M. H.

Myeloid Leukemia C1498 as a Screen for Cancer Chemotherapeutic Agents1

William T. Bradner and M. H. Pindell2

The history of solid myeloid leukemia C1498 is reported; also the maintenance of this tumor in C57BL/6 mice and its use as a screen for antitumor agents are described. In tests with 35 standard agents and fermentation products, C1498 appeared to respond differently from other widely used mouse tumor systems. Cyclophosphamide (NSC-26271) and azaserine (NSC-742) were the most effective inhibitors of C1498 growth. Nine other compounds inhibited the tumor: triethylenemelamine (NSC-9706), methotrexate (NSC-740), 5-fluorouracil (NSC-19893), 2'-deoxy-5-fluorouridine (NSC-27640), prednisone (NSC-10023), 1-aminocyclopentanecarboxylic acid (NSC-1026), N-methylformamide (NSC-3051), hydroxyurea (NSC-32065), methylglyoxal bis(guanylhydrazone) [NSC-32946]. Three antibiotics also produced inhibition: actionomycin D (NSC-3053), mitomycin C (NSC-26980), and phleomycin (NSC-61586). Among the 21 compounds inactive against C1498 were the following well-known materials: busulfan (NSC-750), 6-mercaptopurine (NSC-755), 8-azaguanine (NSC-749), 4-amino-1H-pyrazolo[3,4-d]pyrimidine (NSC-1393), vincaleukblastine (NSC-49842), and leurocristine (NSC-67574). Comparative screening of fermentation filtrates against C1498, Sarcoma 180, and leukemia L1210 indicated specificity on the part of C1498 since the "overlap" rate (response to the same fermentation) with S180 and L1210 was less than 8%.

1 Supported by contract SA-43-ph-2411 from the Cancer Chemotherapy National Service Center, National Cancer Institute, National Institutes of Health, Public Health Service.

2 Research Division, Bristol Laboratories, Syracuse, NY.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1966 by the American Association for Cancer Research.